Neuronetics, Inc. (STIM): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Neuronetics, Inc. (STIM) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. 8-K false 0001227636 0001227636 2026-06-16 2026-06-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) June 16, 2
How this was made
The 30-second read
Why it matters
The main incremental information is the leadership change effective July 1, 2026 and the associated increase in base salary to $425,000 and target discretionary cash bonus to 45% of base salary.
Market read
This is a corporate governance/compensation disclosure with limited direct linkage to near-term financial performance.
What to watch
The filing includes specific compensation terms (base salary and bonus target) but does not disclose equity grant size or any measurable operational outcomes, limiting tradable signal.
Background
The company filed an SEC Form 8-K (Item 5.02) reporting an officer promotion and related changes to employment terms.
Ticker impact
Neuronetics disclosed in an 8-K that it promoted Cory Anderson to EVP/General Manager of Greenbrook effective July 1, 2026 and raised his pay/bonus targets.
Limited near-term impact; any reaction is likely small unless investors view it as signaling strategic shift in Greenbrook operations.
The filing is a routine officer promotion/compensation change (no guidance, deal, or operational metric). Such items typically have low incremental information content for valuation, though they can slightly affect sentiment around leadership/strategy.
Market effects
Minimal; this is an idiosyncratic corporate/HR update rather than a sector catalyst.
None indicated.
None indicated.
Counterpoint
Investors could interpret the Greenbrook general manager appointment as a strategic emphasis on that business line, but the filing provides no performance or roadmap details.
Key entities
- companyNeuronetics, Inc.
Nasdaq-listed medical device company filing the 8-K about an executive promotion and compensation changes.
- executiveCory Anderson
Promoted from SVP, Chief Technology Officer to EVP, General Manager of Greenbrook effective July 1, 2026; base salary and bonus targets increased.
